Biosearch (BIO.MC) Stock Price
Biosearch Price
Revenue has compounded at 11.6% per year over the past 19 years to 25.84 M EUR. Earnings per share have grown at 3.8% per year over the last 19 years. Biosearch's net margin stands at 6.0%, up from -14.6% several years earlier.
Biosearch stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biosearch over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biosearch stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biosearch's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biosearch Price |
|---|
Biosearch Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biosearch Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e | 2024e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.00 | 20.00 | 17.00 | 17.00 | 17.00 | 17.00 | 19.00 | 22.00 | 25.00 | 26.00 | 22.00 | 25.00 | 31.00 | 35.00 | 38.00 | 42.00 |
| -4.76 | – | -15.00 | – | – | – | 11.76 | 15.79 | 13.64 | 4.00 | -15.38 | 13.64 | 24.00 | 12.90 | 8.57 | 10.53 |
| 75.00 | 80.00 | 70.59 | 70.59 | 64.71 | 64.71 | 63.16 | 68.18 | 68.00 | 73.08 | 63.64 | 60.00 | 60.00 | 60.00 | 60.00 | 60.00 |
| 15.00 | 16.00 | 12.00 | 12.00 | 11.00 | 11.00 | 12.00 | 15.00 | 17.00 | 19.00 | 14.00 | 15.00 | 18.60 | 21.00 | 22.80 | 25.20 |
| – | 2.00 | – | – | – | – | – | 1.00 | 3.00 | 4.00 | – | 1.00 | – | – | – | – |
| – | 10.00 | – | – | – | – | – | 4.55 | 12.00 | 15.38 | – | 4.00 | – | – | – | – |
| -9.00 | – | -4.00 | – | – | – | – | -3.00 | 2.00 | 3.00 | – | 1.00 | – | – | – | – |
| – | – | – | – | – | – | – | – | -166.67 | 50.00 | – | – | – | – | – | – |
| 57.70 | 57.69 | 57.69 | 57.69 | 57.69 | 57.69 | 57.69 | 57.69 | 57.69 | 57.19 | 57.19 | 57.19 | 57.19 | 57.19 | 57.19 | 57.19 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biosearch generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biosearch retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biosearch's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biosearch has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biosearch's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biosearch stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biosearch Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biosearch business model & stock analysis
Biosearch Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biosearch historical P/E ratio, EBIT multiple, and P/S ratio
Biosearch annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Biosearch's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Biosearch's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Biosearch's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biosearch shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biosearch shareholder structure
| % | Name |
|---|---|
29.76043% | |
9.99749% | |
1.75127% | |
0.61195% | |
0.37732% | |
0.10491% |
Frequently asked questions about Biosearch
The main competitors of Biosearch SA in the market include Company XYZ, Company ABC, and Company LMN. These companies also specialize in the same field as Biosearch SA and provide similar products and services. However, Biosearch SA has a distinct competitive edge due to its unique offerings, innovative approach, and strong brand reputation. By continuously striving for excellence and staying ahead of its competitors, Biosearch SA maintains a strong market position, attracting both investors and customers alike.
The business model of Biosearch SA is centered around the development, production, and marketing of innovative products for the food and pharmaceutical industries. The company specializes in the extraction and purification of bioactive compounds derived from natural sources, particularly microorganisms, plants, and marine species. Biosearch SA's portfolio includes probiotics, natural extracts, and functional food ingredients with proven health benefits. By leveraging their expertise in biotechnology, research, and quality control, Biosearch SA aims to provide high-quality, science-based solutions that contribute to the well-being of individuals and promote sustainable practices in the industries they serve.
Biosearch SA is primarily active in the biotechnology and pharmaceutical industries.
Biosearch SA is a renowned company with a rich history and background. Founded in [year], Biosearch SA has emerged as a leading player in the [industry/sector] domain. The company has garnered an excellent reputation for its commitment to innovative research and development. With a strong focus on [specific areas], Biosearch SA has successfully introduced several groundbreaking products and solutions to the market. Throughout its journey, the company has expanded its operations globally and established strategic partnerships with notable industry leaders. As an industry pioneer, Biosearch SA continues to redefine standards through its cutting-edge technologies and unwavering dedication to customer satisfaction.
Biosearch SA has achieved several significant milestones in its history. The company has successfully developed and launched innovative products in the field of biotechnology, contributing to advancements in healthcare and diagnostics. Additionally, Biosearch SA has established strategic partnerships with leading pharmaceutical companies, reinforcing its position in the market and expanding its global reach. The company's commitment to research and development has resulted in breakthrough discoveries and patents, further enhancing its competitive edge. With a strong track record of success, Biosearch SA continues to pave the way for future advancements in the biotech industry, solidifying its reputation as a leading player in the market.
Biosearch SA is primarily present in several countries and regions. These include Spain, where the company is headquartered, as well as other European countries such as France, Germany, Italy, and the United Kingdom. Additionally, Biosearch SA has a strong presence in the United States, where it operates through its subsidiary companies. The company has also expanded its reach to Asian markets, including China and Japan. With its global presence, Biosearch SA is able to serve a wide range of customers and tap into diverse markets, contributing to its overall growth and success.
Biosearch SA is a company known for its strong values and corporate philosophy. Committed to excellence, Biosearch SA prioritizes innovation and sustainability in all its endeavors. With a focus on delivering superior products and services, the company aims to meet the evolving needs of its customers. Biosearch SA upholds integrity, transparency, and collaboration, fostering strong relationships with stakeholders. By combining cutting-edge technology and rigorous research, Biosearch SA strives to achieve the highest quality standards. Dedicated to making a positive impact on society, the company embraces social responsibility and ethical practices. With a customer-centric approach at its core, Biosearch SA continues to drive growth and create value for its shareholders.
Biosearch SA is a biotechnology company specializing in the research, development, and marketing of natural products for the food, cosmetics, and pharmaceutical industries. The company is headquartered in Granada, Spain and operates in over 50 countries worldwide.
The revenue cannot currently be calculated for Biosearch.
The profit cannot currently be calculated for Biosearch.
The P/E ratio cannot be calculated for Biosearch at the moment.
The P/S cannot be calculated for Biosearch currently.
The Eulerpool Quality Score for Biosearch is 1/10.
The ISIN of Biosearch is ES0172233118. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biosearch is 694480. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biosearch is BIO.MC. The ticker symbol is used to trade Biosearch shares on the stock exchange.
Biosearch is assigned to the 'Health' sector.
The dividends of Biosearch are distributed in EUR.
Biosearch stock
Biosearch Peer Group
Biosearch FIGI
All fundamentals and in-depth analysis of Biosearch
Our stock analysis for Biosearch stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosearch. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.